The DOI matches its Crossref record; 256 of the 256 references it cites were found in a registry or an index.
Epigenetic modulation and understanding of HDAC inhibitors in cancer therapy
Abstract
The role of genetic and epigenetic factors in tumor initiation and progression is well documented. Histone deacetylases (HDACs), histone methyl transferases (HMTs), and DNA methyl transferases. (DNMTs) are the main proteins that are involved in regulating the chromatin conformation. Among these, histone deacetylases (HDAC) deacetylate the histone and induce gene repression thereby leading to cancer. In contrast, histone acetyl transferases (HATs) that include GCN5, p300/CBP, PCAF, Tip 60 acetylate the histones. HDAC inhibitors are potent drug molecules that can induce acetylation of histones at lysine residues and induce open chromatin conformation at tumor suppressor gene loci and thus resulting in tumor suppression. The key processes regulated by HDAC inhibitors include cell-cycle arrest, chemo-sensitization, apoptosis induction, upregulation of tumor suppressors. Even though FDA approved drugs are confined mainly to haematological malignancies, the research on HDAC inhibitors in glioblastoma multiforme and triple negative breast cancer (TNBC) are providing positive results. Thus, several combinations of HDAC inhibitors along with DNA methyl transferase inhibitors and histone methyl transferase inhibitors are in clinical trials. This review focuses on how HDAC inhibitors regulate the expression of coding and non-coding genes with specific emphasis on their anti-cancer potential.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Items 201–256 of 256
Cao, Y., Choy, E., Hornicek, F. J., Wood, K. B., Schwab, J. H., Liu, X., Mankin, H. J., & Duan, Z. (2010) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-010-1344-7 · Cited by 45
Clear cell carcinoma arising in previous episiotomy scar: a case report and review of the literature
Han, L. N., Zheng, A., & He, W. (2016) · Journal of Ovarian Research · doi:10.1186/s13048-016-0211-5 · Cited by 45
Valdez, B. C., Nieto, Y. L., Murray, D. L., Li, Y., Wang, G., Champlin, R. E., & Andersson, B. S. (2012) · Experimental Hematology · doi:10.1016/j.exphem.2012.06.001 · Cited by 44
Sampson, V. B., Vetter, N. S., Kamara, D., Collier, A. B., Gresh, R. C., & Kolb, E. A. (2015) · PLoS ONE · doi:10.1371/journal.pone.0142704 · Cited by 44
Rao‐Bindal, K., Koshkina, N. V., Stewart, J., & Kleinerman, E. S. (2013) · Current Cancer Drug Targets · doi:10.2174/1568009611313040005 · Cited by 43
Novel Mechanisms of Regulation of miRNAs in CLL
Balatti, V., Acunzo, M., Pekarky, Y., & Croce, C. M. (2016) · Trends in cancer · doi:10.1016/j.trecan.2016.02.005 · Cited by 43
Tharkar-Promod, S., Johnson, D. P., Bennett, S. E., Dennis, E. M., Banowsky, B. G., Jones, S. S., Shearstone, J. R., Quayle, S. N., Min, C., Jarpe, M. B., et al. (2017) · Leukemia · doi:10.1038/leu.2017.174 · Cited by 43
Impact of Histone Deacetylase Inhibitors on microRNA Expression and Cancer Therapy: A Review
Ali, S. R., Humphreys, K. J., McKinnon, R. A., & Michael, M. (2015) · Drug Development Research · doi:10.1002/ddr.21268 · Cited by 42
Souza, B. K., Lopez, P. L. D. C., Menegotto, P. R., Vieira, I. A., Kersting, N., Abujamra, A. L., Brunetto, A. T., Brunetto, A. L., Gregianin, L. J., de Farias, C. B., et al. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-0874-6 · Cited by 42
Deng, Z., Liu, X., Jin, J., Xu, H., Gao, Q., Wang, Y., & Zhao, J. (2016) · International Journal of Biological Sciences · doi:10.7150/ijbs.16569 · Cited by 41
Abbott, D. M., Bortolotto, C., Benvenuti, S., Lancia, A., Filippi, A. R., & Stella, G. M. (2020) · Cancers · doi:10.3390/cancers12051186 · Cited by 41
Ortore, G., Colo, F. D., & Martinelli, A. (2009) · Journal of Chemical Information and Modeling · doi:10.1021/ci900288e · Cited by 40
Monteiro, F. L., Vitorino, R. M. P., Wang, J., Cardoso, H. B., Laranjeira, H., Simões, J., Caldas, M., Henrique, R., Amado, F. M. L., Williams, C., et al. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.03.007 · Cited by 40
Pinto, N. R., DuBois, S. G., Marachelian, A., Diede, S. J., Taraseviciute, A., Bender, J. G., Tsao-Wei, D. D., Groshen, S. G., Reid, J. M., Haas-Kogan, D. A., et al. (2018) · Pediatric Blood & Cancer · doi:10.1002/pbc.27023 · Cited by 40
van den Bijgaart, R. J. E., Kroesen, M., Wassink, M., Brok, I. C., Kers‐Rebel, E. D., Boon, L., Heise, T., van Scherpenzeel, M., Lefeber, D. J., Boltje, T. J., et al. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.002763 · Cited by 40
Garza-Manero, S., Sindi, A. A. A., Mohan, G., Rehbini, O., Jeantet, V., Bailo, M., Latif, F. A., West, M., Gurden, R., Finlayson, L., et al. (2019) · Epigenetics & Chromatin · doi:10.1186/s13072-019-0320-7 · Cited by 39
Fröhlich, L. F., Mrakovcic, M., Smole, C., & Zatloukal, K. (2016) · Cancer Cell International · doi:10.1186/s12935-016-0343-0 · Cited by 38
Rajan, A., Shi, H., & Xue, B. (2018) · Scientific Reports · doi:10.1038/s41598-018-31560-w · Cited by 36
Scott, M. C., Sarver, A. L., Tomiyasu, H., Cornax, I., Etten, J. V., Varshney, J., O’Sullivan, M. G., Subramanian, S., & Modiano, J. F. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.679696 · Cited by 35
Wu, Y.-W., Hsu, K., Lee, H., Huang, T., Lin, T. E., Chen, Y., Sung, T.-Y., Liou, J., Hwang‐Verslues, W. W., Pan, S., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00205 · Cited by 35
Ouaïssi, M., Silvy, F., Sofia, C. L., Giger-Pabst, U., Kevin, Z., Sastre, B., Sielezneff, I., Cordeiro‐da‐Silva, A., Lombardo, D., Mas, E., et al. (2012) · Pancreatology · doi:10.1016/j.pan.2012.02.013 · Cited by 34
The HDAC Inhibitor Vorinostat Diminishes theIn VitroMetastatic Behavior of Osteosarcoma Cells
Mu, X., Brynien, D., & Weiss, K. R. (2015) · BioMed Research International · doi:10.1155/2015/290368 · Cited by 32
HDAC and MAPK/ERK Inhibitors Cooperate To Reduce Viability and Stemness in Medulloblastoma
Jaeger, M. D. C., Ghisleni, E. C., Cardoso, P. S., Siniglaglia, M., Falcón, T., Brunetto, A. T., Brunetto, A. L., de Farias, C. B., Taylor, M. D., Nör, C., et al. (2020) · Journal of Molecular Neuroscience · doi:10.1007/s12031-020-01505-y · Cited by 32
Epigenetic Targeting Therapies to Overcome Chemotherapy Resistance
Balch, C., & Nephew, K. P. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4419-9967-2_14 · Cited by 31
Wen, X., Jeong, S., Kim, Y.-H., Bae, J. M., Cho, N., Kim, J. H., & Kang, G. H. (2017) · Clinical Epigenetics · doi:10.1186/s13148-016-0308-0 · Cited by 31
Lee, H., Lin, C.-H., Lin, H.-Y., Kuei, C., Zheng, J.-Q., Wang, Y., Lu, L., Lee, F., Hu, C., Wu, D., et al. (2019) · Cancers · doi:10.3390/cancers12010098 · Cited by 31
Chaiyawat, P., Pruksakorn, D., Phanphaisarn, A., Teeyakasem, P., Klangjorhor, J., & Settakorn, J. (2017) · Modern Pathology · doi:10.1038/modpathol.2017.125 · Cited by 30
Santos, M. D. L., Zambrano, A., Sánchez‐Pacheco, A., & Aranda, A. (2007) · Molecular Endocrinology · doi:10.1210/me.2007-0151 · Cited by 29
Garrett, L. A., Growdon, W. B., Rueda, B. R., & Foster, R. (2016) · Journal of Ovarian Research · doi:10.1186/s13048-016-0267-2 · Cited by 29
de Almeida, V. R., Vieira, I. A., Buendia, M., Brunetto, A. T., Gregianin, L. J., Brunetto, A. L., Klamt, F., de Farias, C. B., Abujamra, A. L., Lopez, P. L. D. C., et al. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-0250-3 · Cited by 29
Natarajan, U., Venkatesan, T., Radhakrishnan, V., Samuel, S., Rasappan, P., & Rathinavelu, A. (2019) · Medicina · doi:10.3390/medicina55020030 · Cited by 29
Kroesen, M., Brok, I. C., Reijnen, D., Hout-Kuijer, M. A. V., Zeelenberg, I. S., den Brok, M. H., Hoogerbrugge, P. M., & Adema, G. J. (2015) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-015-1663-y · Cited by 28
Li, Y., Liu, T., Ivan, C., Huang, J., Shen, D., Kavanagh, J. J., Bast, R. C., Fu, S., Hu, W., & Sood, A. K. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00058 · Cited by 28
Chatla, S., Swathi, V., Priyanka, C., Devi, T. A., Reddy, B. V. S., Ramaiah, M. J., Bhadra, U., & Bhadra, M. P. (2016) · APOPTOSIS · doi:10.1007/s10495-016-1278-6 · Cited by 28
Self-citationWu, P., Tian, Y. E., Chen, G., Wang, B., Gui, L., Xi, L., Ma, X., Fang, Y., Zhu, T., Wang, D., et al. (2009) · Cell Death and Differentiation · doi:10.1038/cdd.2009.142 · Cited by 27
Bartolucci, S., Mose, R., Longo, A., Mose, R., Estenoz, M., Momparler, R. L., Santoro, B., & Augusti-Tocco, G. (1989) · Cell Differentiation and Development · doi:10.1016/0922-3371(89)90043-9 · Cited by 27
SAHA inhibits the transcription initiation of HPV18 E6/E7 genes in HeLa cervical cancer cells
He, H., Liu, X., Wang, D., Wang, Y., Liu, L., Zhou, H., Luo, X., Wang, N., Ji, B., Luo, Y., et al. (2014) · Gene · doi:10.1016/j.gene.2014.10.007 · Cited by 26
Chen, M.-C., Huang, H.-H., Lai, C.-Y., Lin, Y.-J., Liou, J., Lai, M.-J., Li, Y., Teng, C., & Yang, C. (2015) · Oncotarget · doi:10.18632/oncotarget.6352 · Cited by 26
Han, T., Zhuo, M., Yuan, C., Xiao, X., Cui, J., Qin, G., Wang, L., & Jiao, F. (2020) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2019.0427 · Cited by 26
Maleszewska, M., & Kaminska, B. (2015) · Future Oncology · doi:10.2217/fon.15.171 · Cited by 25
Martile, M. D., Desideri, M., Tupone, M. G., Buglioni, S., Antoniani, B., Mastroiorio, C., Falcioni, R., Ferraresi, V., Baldini, N., Biagini, R., et al. (2018) · Oncogenesis · doi:10.1038/s41389-018-0026-x · Cited by 25
Yelton, C. J., & Ray, S. K. (2018) · Neuroimmunology and Neuroinflammation · doi:10.20517/2347-8659.2018.58 · Cited by 25
Negmeldin, A. T., & Pflum, M. K. H. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.06.033 · Cited by 23
Liu, J., Li, G., Wang, X., Wang, L., Zhao, R., Wang, J., Kong, Y., Ding, J., Li, J., & Zhang, L. (2016) · Translational Oncology · doi:10.1016/j.tranon.2016.01.004 · Cited by 22
BCL-XL is an actionable target for treatment of malignant pleural mesothelioma
Arulananda, S., O’Brien, M., Evangelista, M., Harris, T. J., Steinohrt, N. S., Jenkins, L. J., Walkiewicz, M., O’Donoghue, R. J. J., Poh, A. R., Thapa, B., et al. (2020) · Cell Death Discovery · doi:10.1038/s41420-020-00348-1 · Cited by 22
Ramaiah, M. J., Naushad, S. M., Lavanya, A., Chatla, S., Devi, T. A., Sampathkumar, S., Dharan, D. B., & Bhadra, M. P. (2017) · Gene · doi:10.1016/j.gene.2017.06.031 · Cited by 18
Self-citationTranscriptional suppression of the miR-15/16 family by c-Myc in malignant pleural mesothelioma
Williams, M., Cheng, Y. Y., Kirschner, M. B., Sarun, K. H., Schelch, K., Winata, P., McCaughan, B. C., Kao, S., van Zandwijk, N., & Reid, G. (2019) · Oncotarget · doi:10.18632/oncotarget.27010 · Cited by 17
HDAC Inhibition in Vascular Endothelial Cells Regulates the Expression of ncRNAs
Rafehi, H., & El-Osta, A. (2016) · Non-Coding RNA · doi:10.3390/ncrna2020004 · Cited by 16
Diffuse Large B-Cell Lymphoma and High-Grade B-Cell Lymphoma
Crombie, J. L., & Armand, P. A. (2019) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2019.08.009 · Cited by 15
New Functions of Long Noncoding RNAs during EMT and Tumor Progression
Li, C. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-1205 · Cited by 12
Zheng, R., Chen, X., Wang, C., Qin, P., Tan, H., & Luo, X. (2020) · Case Reports in Hematology · doi:10.1155/2020/8879448 · Cited by 12
Anti-Epileptic Drug Targets Ewing Sarcoma
Kayarthodi, S., Fujimura, Y., Fang, J., Morsalin, S., Rao, V. N., & Reddy, E. S. P. (2014) · Journal of Pharmaceutical Sciences and Pharmacology · doi:10.1166/jpsp.2014.1013 · Cited by 11
Liu, L., Sun, X., Xie, Y., Zhuang, Y., Yao, R., & Xu, K. (2018) · Bioscience Reports · doi:10.1042/bsr20180360 · Cited by 10
Targeting the epigenome of pancreatic cancer for therapy: challenges and opportunities
Baretti, M., Ahuja, N., & Azad, N. S. (2019) · Annals of Pancreatic Cancer · doi:10.21037/apc.2019.10.01 · Cited by 10
Mastoraki, A. T., Schizas, D., Vlachou, P., Melissaridou, N., Charalampakis, N., Fioretzaki, R., Kole, C., Savvidou, O. D., Vassiliu, P., & Pikoulis, E. A. (2020) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-020-00487-2 · Cited by 8
Thiele, C. J., & Reynolds, C. P. (2005) · Springer eBooks · doi:10.1007/3-540-26616-x_15 · Cited by 2
Cited by
Aging and aging-related diseases: from molecular mechanisms to interventions and treatments
Guo, J., Huang, X., Dou, L., Yan, M., Shen, T., Tang, W., & Li, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01251-0 · Cited by 1,718
Regulated cell death (RCD) in cancer: key pathways and targeted therapies
Peng, F., Liao, M., Qin, R., Zhu, S., Peng, C., Fu, L., Chen, Y., & Han, B. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01110-y · Cited by 832
Tumor biomarkers for diagnosis, prognosis and targeted therapy
Zhou, Y., Tao, L., Qiu, J., Xu, J., Yang, X., Zhang, Y., Tian, X., Guan, X., Cen, X., & Zhao, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01823-2 · Cited by 720
The Role of Short Chain Fatty Acids in Inflammation and Body Health
Du, Y., He, C., An, Y., Huang, Y., Zhang, H., Fu, W., Wang, M., Shan, Z., Xie, J., Yang, Y., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137379 · Cited by 384
Recent advances in targeted strategies for triple-negative breast cancer
Zhu, S., Wu, Y., Song, B., Yi, M., Yan, Y., Mei, Q., & Wu, K. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01497-3 · Cited by 331
Metadata
- Authors
- Ramaiah, M. J., Tangutur, A. D., & Manyam, R. R.
- Venue
- Life Sciences
- Publisher
- Elsevier BV
- Published
- 2021-07
- Volume
- 277
- Pages
- 119504
- ISSN
- 0024-3205 (ISSN-L)
- OpenAlex
- W3152901913
- Cited by
- 345
- References
- 256
- FWCI
- 13.69
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.